KR100773621B1 - 4-요오도 페닐아미노 벤즈히드록삼산의 산소화 에스테르 - Google Patents
4-요오도 페닐아미노 벤즈히드록삼산의 산소화 에스테르 Download PDFInfo
- Publication number
- KR100773621B1 KR100773621B1 KR1020037000810A KR20037000810A KR100773621B1 KR 100773621 B1 KR100773621 B1 KR 100773621B1 KR 1020037000810 A KR1020037000810 A KR 1020037000810A KR 20037000810 A KR20037000810 A KR 20037000810A KR 100773621 B1 KR100773621 B1 KR 100773621B1
- Authority
- KR
- South Korea
- Prior art keywords
- benzamide
- phenylamino
- iodo
- difluoro
- hydroxy
- Prior art date
Links
- 0 C*(C)c(cc1C(N*)=O)c(C(C)=*)c(*)c1Nc1c(C)cc(*)cc1 Chemical compound C*(C)c(cc1C(N*)=O)c(C(C)=*)c(*)c1Nc1c(C)cc(*)cc1 0.000 description 2
- VTORJPDWMOIOIQ-UHFFFAOYSA-N CC(C)(C)[SiH](c1ccccc1)c1ccccc1 Chemical compound CC(C)(C)[SiH](c1ccccc1)c1ccccc1 VTORJPDWMOIOIQ-UHFFFAOYSA-N 0.000 description 1
- CNKLVDBLWSVDNZ-UHFFFAOYSA-N CC(C)(OC1)OCC1ON Chemical compound CC(C)(OC1)OCC1ON CNKLVDBLWSVDNZ-UHFFFAOYSA-N 0.000 description 1
- HMFKWZSQGRNWHB-UHFFFAOYSA-N NOCCCCO Chemical compound NOCCCCO HMFKWZSQGRNWHB-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C229/56—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/10—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (82)
- 하기 화학식 (I)의 화합물 또는 이의 약학적으로 허용가능한 염.<화학식 I>상기 식에서,R1은 수소, 할로겐 또는 니트로이고,R2는 수소 또는 불소이고,R3는 수소 또는 불소이고,R4는 수소, 요오드, 브롬, 염소 또는 불소이고,R5는 수소, 할로겐, 히드록시, C1-8 알킬, C1-8 알콕시, 트리플루오로메틸 또는 시아노이고,n은 1 내지 5이고,R6, R7, R8, R9 및 R10은 독립적으로 수소, C1-8 알킬, C3-8 시클로알킬, 히드록시, C1-8 알콕시, 퍼할로 (C1-3) 알킬, 히드록시 (C1-8) 알킬, (C1-5)알콕시(C1-5)알킬, [(C1-4)알킬]2아미노메틸, (C2-7)헤테로사이클 (C1-5)알킬 또는 아릴옥시 (C1-5) 알킬이거나, 또는 독립적으로 결합해 O, S, NH 및 N-알킬로 구성된 군으로부터 선택된 추가의 헤테로원자를 임의로 함유하는 3 내지 10원 시클릭 고리를 완성할 수 있고 (여기서, R7 및 R8은 n > 1인 경우 독립적으로 선택됨),Ra 및 Rb는 독립적으로 수소 또는 C1-4 알킬이고,W는 O이고,R11은 수소, C1-8 알킬, C2-6 알케닐, C3-8 시클로알킬, 히드록시 (C1-8)알킬, (C1-5) 알콕시 (C1-5) 알킬, 페닐, C2-7 헤테로아릴, (C1-8) 알킬카르보닐, (페닐)카르보닐, (페닐)(C1-3 알킬)카르보닐 또는 트리플루오로(C1-6)알킬이고,상기한 알킬기, 알콕시기, 시클로알킬기, 헤테로아릴기 및 페닐기는 히드록시, 아미노, 모노알킬아미노, 디알킬아미노, 할로겐, 시아노, (C1-3) 알콕시, COOR, OCORa, CONRaRb, NRaCORb, SO, SO2, SO4 및 SO2NRaRb로 구성된 군으로부터 독립적으로 선택된 1 내지 5개의 치환기로 임의 치환될 수 있으나,단, R11이 페닐인 경우 n은 1이 아니다.
- 제1항에 있어서, R1이 수소 또는 할로겐인 화합물.
- 제2항에 있어서, 할로겐이 불소, 브롬 또는 염소인 화합물.
- 제1항에 있어서, R2가 불소인 화합물.
- 제1항에 있어서, R3가 불소인 화합물.
- 제1항에 있어서, R4가 요오드인 화합물.
- 제1항에 있어서, R5가 불소, 염소 또는 메틸인 화합물.
- 제1항에 있어서, n이 1 또는 2인 화합물.
- 제1항에 있어서, R6, R7, R8, R9, R10 및 R11 이 수소인 화합물.
- 제1항에 있어서, R6, R7, R8, R9 및 R10이 수소인 화합물.
- 제1항에 있어서, R6, R7, R9, R10 및 R11이 수소인 화합물.
- 삭제
- 삭제
- 제1항에 있어서, R11이 메틸 또는 페닐인 화합물.
- 제1항에 있어서, 하기 화학식 (Ia)의 화합물.<화학식 Ia>상기 식에서,R1은 수소 또는 할로겐이고,R5는 수소, 할로겐 또는 C1-8 알킬이고,R6, R7, R8, R9 및 R10은 독립적으로 수소, C1-8 알킬, 히드록시, C1-8 알콕시, 퍼할로(C1-3) 알킬, (C2-7)헤테로사이클(C1-5) 알킬 또는 아릴옥시 (C1-5) 알킬이거나, 또는 독립적으로 결합해 O, S, NH 및 N-알킬로 구성된 군으로부터 선택된 추가의 헤테로원자를 임의로 함유하는 3 내지 10원 시클릭 고리를 완성할 수 있고(여기서, R7 및 R8은 n > l인 경우 독립적으로 선택됨),R11은 수소, C1-8 알킬, C2-6 알케닐, (C1-5) 알콕시(C1-5)알킬, 페닐, (C1-8)알킬카르보닐 또는 트리플루오로(C1-6) 알킬이다.
- 제15항에 있어서, R1이 수소인 화합물.
- 제15항에 있어서, R3가 수소인 화합물.
- 제15항에 있어서, R3가 불소인 화합물.
- 제15항에 있어서, R4가 요오드인 화합물.
- 제15항에 있어서, R5가 불소, 염소 또는 메틸인 화합물.
- 제15항에 있어서, n이 1 또는 2인 화합물.
- 제15항에 있어서, R6, R7, R8, R9, R10 및 R11 이 수소인 화합물.
- 제15항에 있어서, R6, R7, R8, R9 및 R10이 수소인 화합물.
- 제15항에 있어서, R6, R7, R9, R10 및 R11이 수소인 화합물.
- 삭제
- 삭제
- 제15항에 있어서, R11이 메틸 또는 페닐인 화합물.
- 삭제
- 삭제
- 제1항의 화합물 및 약학적으로 허용가능한 담체를 포함하는,발작, 패혈성 쇼크(septic shock), 심부전, 골관절염(osteoarthritis), 류마티스성 관절염(rheumatoid arthritis), 장기 이식 거부 반응(organ transplant rejection), 종양, 암, 재협착(restenosis), 건선(psoriasis), 죽상경화증(atherosclerosis), 이종 이식 거부 증상, 낭성 섬유증(cystic fibrosis), 당뇨병의 합병증, 간종대(hepatomegaly), 심비대(cardiomegaly), 천식, 알츠하이머병, 만성 또는 신경병증성 통증, 또는 바이러스성 감염을 치료하기 위한 약학 조성물.
- 삭제
- 치료 유효량의 제1항의 화합물 및 약학적으로 허용가능한 담체를 포함하는, 암, 재협착, 건선 및 죽상경화증으로 구성된 군으로부터 선택되는 증식성 질환을 치료하기 위한 약학 조성물.
- 치료 유효량의 제1항의 화합물 및 약학적으로 허용가능한 담체를 포함하는, 건선을 치료하기 위한 약학 조성물.
- 치료 유효량의 제1항의 화합물 및 약학적으로 허용가능한 담체를 포함하는, 암을 치료하기 위한 약학 조성물.
- 제36항에 있어서, 상기 암이 MEK 연관된 것인 약학 조성물.
- 제36항에 있어서, 상기 암이 뇌암, 유방암, 폐암, 난소암, 췌장암, 전립선암, 신장암 또는 대장암인 약학 조성물.
- 치료 유효량의 제1항의 화합물 및 약학적으로 허용가능한 담체를 포함하는, 골관절염을 치료하기 위한 약학 조성물.
- 치료 유효량의 제1항의 화합물 및 약학적으로 허용가능한 담체를 포함하는, 류머티스 관절염을 치료하기 위한 약학 조성물.
- 치료 유효량의 제1항의 화합물 및 약학적으로 허용가능한 담체를 포함하는, 심부전증을 치료하기 위한 약학 조성물.
- 치료 유효량의 제1항의 화합물 및 약학적으로 허용가능한 담체를 포함하는, 만성 통증을 치료하기 위한 약학 조성물.
- 제42항에 있어서, 상기 만성 통증이 신경병증성 통증, 특발성 통증, 만성 알코올중독 관련 통증, 비타민 결핍 관련 통증, 요독증 관련 통증 및 갑상선기능저하증 관련 통증인 약학 조성물.
- 제42항에 있어서, 상기 만성 통증이 염증에 관련된 것인 약학 조성물.
- 제42항에 있어서, 상기 만성 통증이 관절염에 관련된 것인 약학 조성물.
- 제42항에 있어서, 상기 만성 통증이 수술후 통증에 관련된 것인 약학 조성물.
- 치료 유효량의 제1항의 화합물 및 약학적으로 허용가능한 담체를 포함하는, 신경병증성 통증을 치료하기 위한 약학 조성물.
- 제47항에 있어서, 상기 신경병증성 통증이 염증, 수술후 통증, 환지통, 화상통, 통풍, 삼차신경통, 급성 대상포진통과 대상포진후 통증, 작열통, 당뇨병성 신경병증, 신경총 결출상(plexus avulsion), 신경종, 혈관염, 바이러스 감염, 좌상(crush injury), 협착 손상(constriction injury), 조직 손상, 사지절단, 수술후 통증, 관절통 및 말초신경계와 중추신경계 사이의 신경 손상으로 구성된 군으로부터 선택된 증상에 관련된 것인 약학 조성물.
- 치료 유효량의 제1항의 화합물 및 약학적으로 허용가능한 담체를 포함하는, 방사선 요법과 병용하는 암 치료용 약학 조성물.
- 치료 유효량의 제1항의 화합물 및 약학적으로 허용가능한 담체를 포함하는, 1종 이상의 화학요법제와 함께 사용하는 암 치료용 약학 조성물.
- 제50항에 있어서, 상기 화학요법제가 유사분열 억제제인 약학 조성물.
- 제51항에 있어서, 상기 유사분열 억제제가 파클리탁셀(paclitaxel), 도세탁셀(docetaxel), 빈크리스틴(vincristine), 빈블라스틴(vinblastine), 비노렐빈(vinorelbine) 및 빈플루닌(vinflunine)으로 구성된 군으로부터 선택된 것인 약학 조성물.
- CuKα방사선을 사용해 측정된 2θ값들인 7.1, 19.2 또는 32.1 중에서 1 이상을 포함하는 X-선 회절 분말 회절을 갖는, 결정질 형태 (I) N-(2,3-디히드록시-프로폭시)-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)벤즈아미드.
- CuKα방사선을 사용해 측정된 2θ값들인 7.1, 19.2 및 32.1를 포함하는 X-선 회절 분말 회절을 갖는 결정질 형태 (I) N-(2,3-디히드록시-프로폭시)-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-벤즈아미드.
- CuKα방사선을 사용해 측정된 2θ값들인 7.1, 14.1, 15.3, 15.8, 16.9, 18.1, 19.2, 20.3, 21.4, 22.3, 23.4, 24.5, 25.5, 26.2, 26.8, 27.8, 28.3, 29.5, 32.1, 33.2, 33.6, 40.0, 42.9 및 44.1를 포함하는 X-선 회절 분말 회절을 갖는 결정질 형태 (I) N-(2,3-디히드록시-프로폭시)-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-벤즈아미드.
- CuKα방사선을 사용해 측정된 2θ값들인 7.078, 14.123, 15.280, 15.836, 16.880, 18.082, 19.162, 20.279, 21.360, 22.325, 23.400, 24.522, 25.480, 26.159, 26.801, 27.842, 28.280, 29.475, 32.118, 33.248, 33.645, 40.008, 42.885 및 44.095를 포함하는 X-선 회절 분말 회절을 갖는 결정질 형태 (I) N-[2,3-디히드록시-프로폭시]-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-벤즈아미드.
- CuKα방사선을 사용해 측정된 2θ값들인 11.6, 12.6 또는 24.9 중에서 1 이상을 포함하는 X-선 회절 분말 회절을 갖는 결정질 형태 (II) N-(2,3-디히드록시-프로폭시)-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-벤즈아미드.
- CuKα방사선을 사용해 측정된 2θ값들인 11.6, 12.6 및 24.9를 포함하는 X-선 회절 분말 회절을 갖는 결정질 형태 (II) N-(2,3-디히드록시-프로폭시)-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-벤즈아미드.
- CuKα방사선을 사용해 측정된 2θ값들인 11.6, 12.6, 15.6, 17.3, 17.9, 20.3, 21.1, 22.1, 24.9, 25.9, 26.7, 27.8, 30.1, 30.9, 33.8, 35.4, 38.2, 39.3, 40.8, 41.6, 43.6 및 47.0을 포함하는 X-선 회절 분말 회절을 갖는 결정질 형태 (II) N-(2,3-디히드록시-프로폭시)-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-벤즈아미드.
- CuKα방사선을 사용해 측정된 2θ값들인 11.582, 12.598, 15.622, 17.302, 17.886, 20.345, 21.140, 22.137, 24.855, 25.885, 26.699, 27.842, 30.059, 30.948, 33.799, 35.399, 38.242, 39.282, 40.755, 41.641, 43.570 및 46.958을 포함하는 X-선 회절 분말 회절을 갖는 결정질 형태 (II) N-(2,3-디히드록시-프로폭시)-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-벤즈아미드.
- CuKα방사선을 사용해 측정된 2θ값들인 10.6, 13.7, 19.0 또는 23.7 중에서 1 이상을 포함하는 X-선 회절 분말 회절을 갖는 결정질 형태 (I) N-[(R)-2,3-디히드록시-프로폭시]-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)벤즈아미드.
- CuKα방사선을 사용해 측정된 2θ값들인 10.6, 13.7, 19.0 및 23.7를 포함하는 X-선 회절 분말 회절을 갖는 결정질 형태 (I) N-[(R)-2,3-디히드록시-프로폭시]-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)벤즈아미드.
- CuKα방사선을 사용해 측정된 2θ값들인 10.6, 13.7, 14.6, 17.3, 18.0, 18.2, 98.0, 19.3, 20.1, 21.0, 21.9, 22.4, 23.7, 24.0, 24.9, 26.3, 27.6, 28.0, 30.1, 32.1, 32.3, 32.9, 35.8 및 37.7을 포함하는 X-선 회절 분말 회절을 갖는 결 정질 형태 (I) N-[(R)-2,3-디히드록시-프로폭시]-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)벤즈아미드.
- CuKα방사선을 사용해 측정된 2θ값들인 10.560, 13.720, 14.619, 17.258, 17.958, 18.219, 18.998, 19.258, 20.142, 21.002, 21.940, 22.360, 23.680, 24.043, 24.919, 26.278, 27.603, 28.024, 30.100, 32.142, 32.298, 32.938, 35.841 및 37.660을 포함하는 X-선 회절 분말 회절을 갖는 결정질 형태 (I) N-[(R)-2,3-디히드록시-프로폭시]-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)벤즈아미드.
- CuKα방사선을 사용해 측정된 2θ값들인 5.5 또는 19.6 중에서 1 이상을 포함하는 X-선 회절 분말 회절을 갖는 결정질 형태 (II) N-[(R)-2,3-디히드록시-프로폭시]-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)벤즈아미드.
- CuKα방사선을 사용해 측정된 2θ값들인 5.5 및 19.6을 포함하는 X-선 회절 분말 회절을 갖는 결정질 형태 (II) N-[(R)-2,3-디히드록시-프로폭시]-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-벤즈아미드.
- CuKα방사선을 사용해 측정된 2θ값들인 5.5, 10.7, 16.5, 19.6, 22.0, 22.5, 23.6, 24.1, 25.0, 26.2, 27.6, 29.1, 30.5, 31.7, 33.3 및 39.0을 포함하는 X-선 회절 분말 회절을 갖는 결정질 형태 (II) N-[(R)-2,3-디히드록시-프로폭시]-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)벤즈아미드.
- CuKα방사선을 사용해 측정된 2θ값들인 5.482, 10.721, 16.478, 19.563, 22.019, 22.478, 23.621, 24.100, 24.959, 26.181, 27.621, 29.081, 30.476, 31.698, 33.263 및 39.020을 포함하는 X-선 회절 분말 회절을 갖는 결정질 형태 (II) N-[(R)-2,3-디히드록시-프로폭시]-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)벤즈아미드.
- CuKα방사선을 사용해 측정된 2θ값들인 10.5, 13.7, 19.0, 또는 23.6 중 1 이상을 포함하는 X-선 회절 분말 회절을 갖는 결정질 형태 (I) N-[(S)-2,3-디히드록시-프로폭시]-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-벤즈아미드.
- CuKα방사선을 사용해 측정된 2θ값들인 10.5, 13.7, 19.0, 및 23.6을 포함하는 X-선 회절 분말 회절을 갖는 결정질 형태 (I) N-[(S)-2,3-디히드록시-프로폭시]-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-벤즈아미드.
- CuKα방사선을 사용해 측정된 2θ값들인 10.548, 13.703, 17.887, 18.958, 20.122, 21.950, 22.321, 23.640, 24.803, 26.244, 27.570, 28.000, 29.566, 32.234, 32.769, 35.804, 37.641, 41.402, 41.956 및 44.600을 포함하는 X-선 회절 분말 회절을 갖는 결정질 형태 (I) N-[(S)-2,3-디히드록시-프로폭시]-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)벤즈아미드.
- CuKα방사선을 사용해 측정된 2θ값들인 10.548, 13.703, 17.887, 18.958, 20.122, 21.950, 22.321, 23.640, 24.803, 26.244, 27.570, 28.000, 29.566, 32.234, 32.769, 35.804, 37.641, 41.402, 41.956 및 44.600을 포함하는 X-선 회절 분말 회절을 갖는 결정질 형태 (I) N-[(S)-2,3-디히드록시-프로폭시]-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)벤즈아미드.
- CuKα방사선을 사용해 측정된 2θ값들인 5.6 또는 19.6 중 에서 1 이상을 포함하는 X-선 회절 분말 회절을 갖는 결정질 형태 (II) N-[(S)-2,3-디히드록시-프로폭시]-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-벤즈아미드.
- CuKα방사선을 사용해 측정된 2θ값들인 5.6 및 19.6을 포함하는 X-선 회절 분말 회절을 갖는 결정질 형태 (II) N-[(S)-2,3-디히드록시-프로폭시]-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-벤즈아미드.
- CuKα방사선을 사용해 측정된 2θ값들인 5.6, 10.7, 16.5, 19.6, 20.9, 22.0, 23.7, 24.2, 25.0, 26.2, 27.7, 28.0, 29.1, 31.7, 32.8, 33.3, 34.1, 42.0 및 42.3을 포함하는 X-선 회절 분말 회절을 갖는 결정질 형태 (II) N-[(S)-2,3-디히드록시-프로폭시]-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-벤즈아미드.
- CuKα방사선을 사용해 측정된 2θ값들인 5.550, 10.763, 16.485, 19.636, 20.922, 22.043, 23.683, 24.153, 24.996, 26.236, 27.680, 28.037, 29.120, 31.718, 32.794, 33.314, 34.085, 41.999 및 42.278을 포함하는 X-선 회절 분말 회절을 갖는 결정질 형태 (II) N-[(S)-2,3-디히드록시-프로폭시]-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-벤즈아미드.
- 5-클로로-2-(2-클로로-4-요오도-페닐아미노)-N-(2,3-디히드록시-프로폭시)-3,4-디플루오로-벤즈아미드,3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(2-히드록시-에톡시)-벤즈아미드,N-(2,3-디히드록시-프로폭시)-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)벤즈아미드,5-클로로-N-(2,3-디히드록시-프로폭시)-3,4-디플루오로-2-(2-플루오로-4-요오도페닐아미노)-벤즈아미드,5-클로로-N-((R)-2,3-디히드록시-프로폭시)-3,4-디플루오로-2-(2-플루오로-4-요오도페닐아미노)-벤즈아미드,N-((R)-2,3-디히드록시-프로폭시)-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)벤즈아미드,N-((S)-2,3-디히드록시-프로폭시)-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)벤즈아미드,5-클로로-2-(2-클로로-4-요오도-페닐아미노)-N-((S)-2,3-디히드록시-프로폭시)-3,4-디플루오로-벤즈아미드,5-클로로-2-(2-클로로-4-요오도-페닐아미노)-N-((R)-2,3-디히드록시-프로폭시)-3,4-디플루오로-벤즈아미드,5-클로로-N-((S) 2,3-디히드록시-프로폭시)-3,4-디플루오로-2-(2-플루오로-4-요오도페닐아미노)-벤즈아미드,3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(2-히드록시-1-히드록시메틸에톡시)-벤즈아미드 및5-클로로-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(2-히드록시-1-히드록시메틸-에톡시)-벤즈아미드로 구성된 군으로부터 선택된 화합물.
- 3,4,5-트리플루오로-N-(2-히드록시-에톡시)-2-(4-요오도-2-메틸-페닐아미노) 벤즈아미드,3,4-디플루오로-N-(2-히드록시-에톡시)-2-(4-요오도-2-메틸-페닐아미노) 벤즈아미드,2-(2-클로로-4-요오도-페닐아미노)-3,4-디플루오로-N-(2-히드록시-에톡시)- 벤즈아미드,2-(2-클로로-4-요오도-페닐아미노)-4-플루오로-N-(2-히드록시-에톡시)-벤즈아미드,4-플루오로-N-(2-히드록시-에톡시)-2-(4-요오도-2-메틸-페닐아미노) 벤즈아미드,2-(2-클로로-4-요오도-페닐아미노)-3,4,5-트리플루오로-N-(2-히드록시-에톡시) 벤즈아미드,5-클로로-3,4-디플루오로-N-(2-히드록시-에톡시)-2-(4-요오도-페닐아미노) 벤즈아미드,4-플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(2-히드록시-에톡시)-벤즈아미드,3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(2-히드록시-에톡시) 벤즈아미드,5-클로로-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(2-히드록시 에톡시)-벤즈아미드,5-브로모-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(2-히드록시 에톡시)-벤즈아미드,4,5-디플루오로-N-(2-히드록시-에톡시)-2-(4-요오도-2-메틸-페닐아미노) 벤즈아미드,5-브로모-3,4-디플루오로-N-(2-히드록시-에톡시)-2-(4-요오도-2-메틸 페닐아미노)-벤즈아미드,5-브로모-2-(2-클로로-4-요오도-페닐아미노)-3,4-디플루오로-N-(2-히드록시- 에톡시)-벤즈아미드,5-클로로-3,4-디플루오로-N-(2-히드록시-에톡시)-2-(4-요오도-2-메틸 페닐아미노)-벤즈아미드,5-브로모-4-플루오로-N-(2-히드록시-에톡시)-2-(4-요오도-2-메틸 페닐아미노)-벤즈아미드,2-(2-클로로-4-요오도-페닐아미노)-4,5-디플루오로-N-(2-히드록시-에톡시)- 벤즈아미드,4,5-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(2-히드록시-에톡시) 벤즈아미드,5-브로모-4-플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(2-히드록시- 에톡시)-벤즈아미드,5-클로로-2-(2-클로로-4-요오도-페닐아미노)-3,4-디플루오로-N-(2-히드록시- 에톡시)-벤즈아미드,3,4,5-트리플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(2-히드록시-에톡시) 벤즈아미드,2-(4-브로모-2-플루오로-페닐아미노)-3,4-디플루오로-N-(2-히드록시-에톡시)-벤즈아미드,2-(4-브로모-2-플루오로-페닐아미노)-4,5-디플루오로-N-(2-히드록시-에톡시)-벤즈아미드,2-(4-클로로-2-플루오로-페닐아미노)-3,4-디플루오로-N-(2-히드록시-에톡시)-벤즈아미드,3,4-디플루오로-2-(2-플루오로-페닐아미노)-N-(2-히드록시-에톡시) 벤즈아미드,5-클로로-2-(2,4-디플루오로-페닐아미노)-3,4-디플루오로-N-(2-히드록시 에톡시)-벤즈아미드,2-(2,4-디플루오로-페닐아미노)-3,4-디플루오로-N-(2-히드록시-에톡시) 벤즈아미드,4-플루오로-N-(3-히드록시-프로폭시)-2-(4-요오도-2-메틸-페닐아미노)-벤즈아미드,5-클로로-3,4-디플루오로-N-(3-히드록시-프로폭시)-2-(4-요오도-2-메틸 페닐아미노)-벤즈아미드,2-(2-클로로-4-요오도-페닐아미노)-4-플루오로-N-(3-히드록시-프로폭시)-벤즈아미드,5-브로모-2-(2-클로로-4-요오도-페닐아미노)-3,4-디플루오로-N-(3-히드록시- 프로폭시)-벤즈아미드,3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(3-히드록시-프로폭시) 벤즈아미드,3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(4-히드록시-부톡시) 벤즈아미드,5-클로로-2-(2-클로로-4-요오도-페닐아미노)-N-(2,3-디히드록시-프로폭시)-3,4-디플루오로-벤즈아미드,5-클로로-N-(2,3-디히드록시-프로폭시)-3,4-디플루오로-2-(4-요오도-2-메틸 페닐아미노)-벤즈아미드,5-클로로-N-(3,4-디히드록시-부톡시)-3,4-디플루오로-2-(4-요오도-2-메틸- 페닐아미노)-벤즈아미드,5-클로로-2-(2-클로로-4-요오도-페닐아미노)-N-(3,4-디히드록시-부톡시)-3,4-디플루오로-벤즈아미드,N-(2, 2-디메틸-1, 3-디옥솔란-4-일메톡시)-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-벤즈아미드,N-(2,3-디히드록시-프로폭시)-3,4-디플루오로-2-(2-플루오로-4-요오도 페닐아미노)-벤즈아미드,5-브로모-N-(2,3-디히드록시-프로폭시)-3,4-디플루오로-2-(2-플루오로-4-요오도 페닐아미노)-벤즈아미드,5-클로로-N-(2,3-디히드록시-프로폭시)-3,4-디플루오로-2-(2-플루오로-4-요오도 페닐아미노)-벤즈아미드,N-(2,3-디히드록시-프로폭시)-4-플루오로-2-(2-플루오로-4-요오도-페닐아미노)-벤즈아미드,N-(2,3-디히드록시-프로폭시)-3,4,5-트리플루오로-2-(2-플루오로-4-요오도 페닐아미노)-벤즈아미드,2-(4-브로모-2-플루오로-페닐아미노)-N-(2,3-디히드록시-프로폭시)-3,4-디플루오로-벤즈아미드,2-(4-클로로-2-플루오로-페닐아미노)-N-(2,3-디히드록시-프로폭시)-3,4 디플루오로-벤즈아미드,N-(2,2-디메틸-1,3-디옥시난-5-일옥시)-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-벤즈아미드,3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(2-히드록시-1-히드록시메틸-에톡시)-벤즈아미드,5-클로로-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(2-히드록시-1-히드록시메틸-에톡시)-벤즈아미드,N-((R)-2,3-디히드록시-프로폭시)-3,4-디플루오로-2-(2-플루오로-4-요오도 페닐아미노)-벤즈아미드,N-((S)-2,3-디히드록시-프로폭시)-3,4-디플루오로-2-(2-플루오로-4-요오도 페닐아미노)-벤즈아미드,5-클로로-2-(2-클로로-4-요오도-페닐아미노)-N-((R)-2,3-디히드록시-프로폭시)-3,4-디플루오로-벤즈아미드,5-클로로-2-(2-클로로-4-요오도-페닐아미노)-N-((S)-2,3-디히드록시-프로폭시)-3,4-디플루오로-벤즈아미드,5-클로로-N-((R)-2,3-디히드록시-프로폭시)-3,4-디플루오로-2-(2-플루오로-4 요오도-페닐아미노)-벤즈아미드,5-클로로-N-((S)-2,3-디히드록시-프로폭시)-3,4-디플루오로-2-(2-플루오로-4-요오도 페닐아미노)-벤즈아미드,2-(4-브로모-2-플루오로-페닐아미노)-N-((R)-2,3-디히드록시-프로폭시)-3,4 디플루오로-벤즈아미드,2-(2-클로로-4-요오도-페닐아미노)-3,4-디플루오로-N-(2-비닐옥시-에톡시)- 벤즈아미드,2-(2-클로로-4-요오도-페닐아미노)-3,4,5-트리플루오로-N-(2-비닐옥시-에톡시) 벤즈아미드,4-플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(2-비닐옥시-에톡시)-벤즈아미드,3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(2-비닐옥시-에톡시) 벤즈아미드,5-클로로-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(2-비닐옥시 에톡시)-벤즈아미드,5-브로모-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(2-비닐옥시 에톡시)-벤즈아미드,5-브로모-2-(2-클로로-4-요오도-페닐아미노)-3,4-디플루오로-N-(2-히드록시-1,1-디메틸-에톡시)-벤즈아미드,3,4-디플루오로-N-(2-히드록시-1,1-디메틸-에톡시)-2-(4-요오도-2-메틸 페닐아미노)-벤즈아미드,2-(2-클로로-4-요오도-페닐아미노)-3,4-디플루오로-N-(2-히드록시-2-메틸- 프로폭시)-벤즈아미드,3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(2-히드록시-1,1-디메틸-에톡시)-벤즈아미드,5-클로로-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(2-히드록시-1,1-디메틸-에톡시)-벤즈아미드,3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(2-히드록시-2-메틸 프로폭시)-벤즈아미드,3,4-디플루오로-N-(2-히드록시-3-메톡시-프로폭시)-2-(4-요오도-2-메틸 페닐아미노)-벤즈아미드,5-브로모-2-(2-클로로-4-요오도-페닐아미노)-3,4-디플루오로-N-(2-히드록시-3-메톡시-프로폭시)-벤즈아미드,3,4-디플루오로-N-(1-히드록시메틸-시클로프로필메톡시)-2-(4-요오도-2-메틸-페닐아미노)-벤즈아미드,5-브로모-2-(2-클로로-4-요오도-페닐아미노)-3,4-디플루오로-N-(1-히드록시메틸-시클로프로필메톡시)-벤즈아미드,3,4-디플루오로-2-(4-요오도-2-메틸-페닐아미노)-N-(3,3,3-트리플루오로-2 히드록시-프로폭시)-벤즈아미드,5-브로모-2-(2-클로로-4-요오도-페닐아미노)-3,4-디플루오로-N-(3,3,3-트리플루오로-2-히드록시-프로폭시)-벤즈아미드,3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(2-히드록시메틸 시클로프로필메톡시)-벤즈아미드,5-클로로-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(2-히드록시메틸-시클로프로필메톡시)-벤즈아미드,N-(2,3-디히드록시-3-메틸-부톡시)-3,4-디플루오로-2-(2-플루오로-4-요오도- 페닐아미노)-벤즈아미드,2-(2-클로로-4-요오도-페닐아미노)-4-플루오로-N-(2-히드록시-에톡시)-N-메틸-벤즈아미드,아세트산 2-[3,4,5-트리플루오로-2-(4-요오도-2-메틸-페닐아미노) 벤조일아미노옥시]-에틸 에스테르,[3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-페닐]-(4-히드록시- 이속사졸리딘-2-일)-메탄온,5-브로모-N-(2,3-디히드록시-프로폭시)-3,4-디플루오로-2-(2-플루오로 페닐아미노)-벤즈아미드,N-(2,3-디히드록시-프로폭시)-3,4-디플루오로-2-(2-플루오로-페닐아미노) 벤즈아미드,2-(2-클로로-4-요오도-페닐아미노)-N-(2,3-디히드록시-프로폭시)-3,4-디플루오로-벤즈아미드,2-(2-클로로-4-요오도-페닐아미노)-N-(2,3-디히드록시-프로폭시)-3,4,5 트리플루오로-벤즈아미드,5-브로모-2-(2-클로로-4-요오도-페닐아미노)-N-(2,3-디히드록시-프로폭시)-3,4-디플루오로-벤즈아미드,N-(2,3-디히드록시-프로폭시)-3,4-디플루오로-2-(4-요오도-2-메틸 페닐아미노)-벤즈아미드,N-(2,3-디히드록시-프로폭시)-3,4,5-트리플루오로-2-(4-요오도-2-메틸 페닐아미노)-벤즈아미드,5-브로모-N-(2,3-디히드록시-프로폭시)-3,4-디플루오로-2-(4-요오도-2-메틸 페닐아미노)-벤즈아미드,2-(2-클로로-4-요오도-페닐아미노)-N-(3,4-디히드록시-부톡시)-3,4 디플루오로-벤즈아미드,2-(2-클로로-4-요오도-페닐아미노)-N-(3,4-디히드록시-부톡시)-3,4,5 트리플루오로-벤즈아미드,5-브로모-2-(2-클로로-4-요오도-페닐아미노)-N-(3,4-디히드록시-부톡시)-3,4-디플루오로-벤즈아미드,N-(3,4-디히드록시-부톡시)-3,4-디플루오로-2-(4-요오도-2-메틸페닐아미노)-벤즈아미드,N-(3,4-디히드록시-부톡시)-3,4,5-트리플루오로-2-(4-요오도-2-메틸 페닐아미노)-벤즈아미드,5-브로모-N-(3,4-디히드록시-부톡시)-3,4-디플루오로-2-(4-요오도-2-메틸 페닐아미노)-벤즈아미드,5-브로모-2-(2-클로로-4-요오도-페닐아미노)-3,4-디플루오로-N-(3-히드록시- 프로폭시)-벤즈아미드,2-(2-클로로-4-요오도-페닐아미노)-3,4-디플루오로-N-(3-히드록시-프로폭시)-벤즈아미드,3,4,5-트리플루오로-N-(3-히드록시-프로폭시)-2-(4-요오도-2-메틸 페닐아미노)-벤즈아미드,2-(2-클로로-4-요오도-페닐아미노)-3,4,5-트리플루오로-N-(3-히드록시-프로폭시) 벤즈아미드,5-브로모-3,4-디플루오로-N-(3-히드록시-프로폭시)-2-(4-요오도-2-메틸 페닐아미노)-벤즈아미드,3,4-디플루오로-N-(3-히드록시-프로폭시)-2-(4-요오도-2-메틸-페닐아미노) 벤즈아미드,2-(2-클로로-4-요오도-페닐아미노)-3,4-디플루오로-N-(2-히드록시-부톡시)- 벤즈아미드,2-(2-클로로-4-요오도-페닐아미노)-3,4,5-트리플루오로-N-(2-히드록시-부톡시) 벤즈아미드,3,4,5-트리플루오로-N-(2-히드록시-부톡시)-2-(4-요오도-2-메틸-페닐아미노) 벤즈아미드,5-브로모-2-(2-클로로-4-요오도-페닐아미노)-3,4-디플루오로-N-(2-히드록시- 부톡시)-벤즈아미드,5-브로모-3,4-디플루오로-N-(2-히드록시-부톡시)-2-(4-요오도-2-메틸 페닐아미노)-벤즈아미드,3,4-디플루오로-N-(2-히드록시-부톡시)-2-(4-요오도-2-메틸-페닐아미노) 벤즈아미드,5-클로로-2-(2-클로로-4-요오도-페닐아미노)-3,4-디플루오로-N-(2-히드록시- 부톡시)-벤즈아미드,5-클로로-3,4-디플루오로-N-(2-히드록시-부톡시)-2-(4-요오도-2-메틸 페닐아미노)-벤즈아미드,3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(2-히드록시-부톡시) 벤즈아미드,5-브로모-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(2-히드록시 부톡시)-벤즈아미드,5-클로로-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(2-히드록시 부톡시)-벤즈아미드,4,5-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(2-히드록시-부톡시) 벤즈아미드,5-클로로-2-(2,4-디플루오로-페닐아미노)-3,4-디플루오로-N-(2-히드록시 부톡시)-벤즈아미드,2-(2,4-디플루오로-페닐아미노)-3,4-디플루오로-N-(2-히드록시-부톡시)-벤즈아미드,2-(4-브로모-2-플루오로-페닐아미노)-3,4-디플루오로-N-(2-히드록시-부톡시)-벤즈아미드,5-클로로-3,4-디플루오로-N-(2-히드록시-1-메틸-에톡시)-2-(4-요오도-2 메틸-페닐아미노)-벤즈아미드,2-(2-클로로-4-요오도-페닐아미노)-3,4-디플루오로-N-(2-히드록시-1-메틸 에톡시)-벤즈아미드,2-(2-클로로-4-요오도-페닐아미노)-3,4,5-트리플루오로-N-(2-히드록시-1-메틸 에톡시)-벤즈아미드,3,4,5-트리플루오로-N-(2-히드록시-1-메틸-에톡시)-2-(4-요오도-2-메틸 페닐아미노)-벤즈아미드,5-브로모-2-(2-클로로-4-요오도-페닐아미노)-3,4-디플루오로-N-(2-히드록시-1-메틸-에톡시)-벤즈아미드,5-브로모-3,4-디플루오로-N-(2-히드록시-1-메틸-에톡시)-2-(4-요오도-2-메틸-페닐아미노)-벤즈아미드,2-(4-클로로-2-플루오로-페닐아미노)-3,4-디플루오로-N-(2-히드록시-1-메틸- 에톡시)-벤즈아미드,3,4-디플루오로-N-(2-히드록시-1-메틸-에톡시)-2-(4-요오도-2-메틸 페닐아미노)-벤즈아미드,5-클로로-2-(2-클로로-4-요오도-페닐아미노)-3,4-디플루오로-N-(2-히드록시-l-메틸-에톡시)-벤즈아미드,3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(2-히드록시-l-메틸 에톡시)-벤즈아미드,5-브로모-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(2-히드록시-1-메틸-에톡시)-벤즈아미드,5-클로로-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(2-히드록시-1-메틸-에톡시)-벤즈아미드,4,5-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(2-히드록시-1-메틸 에톡시)-벤즈아미드,5-클로로-2-(2,4-디플루오로-페닐아미노)-3,4-디플루오로-N-(2-히드록시-1- 메틸-에톡시)-벤즈아미드,2-(2,4-디플루오로-페닐아미노)-3,4-디플루오로-N-(2-히드록시-1-메틸-에톡시)-벤즈아미드,2-(2-클로로-4-요오도-페닐아미노)-3,4-디플루오로-N-(2-메톡시-에톡시)-벤즈아미드,2-(2-클로로-4-요오도-페닐아미노)-3,4,5-트리플루오로-N-(2-메톡시-에톡시) 벤즈아미드,3,4-디플루오로-2-(4-요오도-2-메틸-페닐아미노)-N-(2-메톡시-에톡시) 벤즈아미드,5-브로모-3,4-디플루오로-2-(4-요오도-2-메틸-페닐아미노)-N-(2-메톡시-에톡시)-벤즈아미드,3,4,5-트리플루오로-2-(4-요오도-2-메틸-페닐아미노)-N-(2-메톡시-에톡시) 벤즈아미드,5-브로모-2-(2-클로로-4-요오도-페닐아미노)-3,4-디플루오로-N-(2-메톡시- 에톡시)-벤즈아미드,5-클로로-2-(2-클로로-4-요오도-페닐아미노)-3,4-디플루오로-N-(2-메톡시- 에톡시)-벤즈아미드,5-클로로-3,4-디플루오로-2-(4-요오도-2-메틸-페닐아미노)-N-(2-메톡시-에톡시)-벤즈아미드,5-클로로-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(2-메톡시 에톡시)-벤즈아미드,2-(2-클로로-4-요오도-페닐아미노)-3,4-디플루오로-N-(2-히드록시-3-모르폴린-4-일-프로폭시)-벤즈아미드,5-브로모-2-(2-클로로-4-요오도-페닐아미노)-3,4-디플루오로-N-(2-히드록시-3-모르폴린-4-일-프로폭시)-벤즈아미드,2-(2-클로로-4-요오도-페닐아미노)-3,4,5-트리플루오로-N-(2-히드록시-3-모르폴린-4-일-프로폭시)-벤즈아미드,3,4,5-트리플루오로-N-(2-히드록시-3-모르폴린-4-일-프로폭시)-2-(4-요오도-2-메틸-페닐아미노)-벤즈아미드,5-브로모-3,4-디플루오로-N-(2-히드록시-3-모르폴린-4-일-프로폭시)-2-(4-요오도-2-메틸-페닐아미노)-벤즈아미드,3,4-디플루오로-N-(2-히드록시-3-모르폴린-4-일-프로폭시)-2-(4-요오도-2-메틸-페닐아미노)-벤즈아미드,5-클로로-2-(2-클로로-4-요오도-페닐아미노)-3,4-디플루오로-N-(2-히드록시-3-모르폴린-4-일-프로폭시)-벤즈아미드,5-클로로-3,4-디플루오로-N-(2-히드록시-3-모르폴린-4-일-프로폭시)-2-(4-요오도-2-메틸-페닐아미노)-벤즈아미드,3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(2-히드록시-3-모르폴린-4-일-프로폭시)-벤즈아미드,5-클로로-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(2-히드록시-3-모르폴린-4-일-프로폭시)-벤즈아미드,4,5-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(2-히드록시-3-모르폴린-4-일-프로폭시)-벤즈아미드,5-클로로-2-(2,4-디플루오로-페닐아미노)-3,4-디플루오로-N-(2-히드록시-3 모르폴린-4-일-프로폭시)-벤즈아미드,2-(4-클로로-2-플루오로-페닐아미노)-3,4-디플루오로-N-(2-히드록시-3-모르폴린-4-일-프로폭시)-벤즈아미드,2-(2-클로로-4-요오도-페닐아미노)-3,4-디플루오로-N-(2-히드록시-프로폭시)-벤즈아미드,3,4,5-트리플루오로-N-(2-히드록시-프로폭시)-2-(4-요오도-2-메틸 페닐아미노)-벤즈아미드,5-브로모-2-(2-클로로-4-요오도-페닐아미노)-3,4-디플루오로-N-(2-히드록시- 프로폭시)-벤즈아미드,5-브로모-3,4-디플루오로-N-(2-히드록시-프로폭시)-2-(4-요오도-2-메틸 페닐아미노)-벤즈아미드,2-(2-클로로-4-요오도-페닐아미노)-3,4,5-트리플루오로-N-(2-히드록시-프로폭시) 벤즈아미드,5-클로로-2-(2-클로로-4-요오도-페닐아미노)-3,4-디플루오로-N-(2-히드록시- 프로폭시)-벤즈아미드,3,4-디플루오로-N-(2-히드록시-프로폭시)-2-(4-요오도-2-메틸-페닐아미노) 벤즈아미드,5-클로로-3,4-디플루오로-N-(2-히드록시-프로폭시)-2-(4-요오도-2-메틸 페닐아미노)-벤즈아미드,3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(2-히드록시-프로폭시) 벤즈아미드,5-클로로-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(2-히드록시 프로폭시)-벤즈아미드,5-클로로-2-(2,4-디플루오로-페닐아미노)-3,4-디플루오로-N-(2-히드록시-프로폭시)-벤즈아미드,2-(2,4-디플루오로-페닐아미노)-3,4-디플루오로-N-(2-히드록시-프로폭시) 벤즈아미드,2-(4-클로로-2-플루오로-페닐아미노)-3,4-디플루오로-N-(2-히드록시-프로폭시)-벤즈아미드,4,5-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(2-히드록시-프로폭시) 벤즈아미드,2-(2-클로로-4-요오도-페닐아미노)-3,4,5-트리플루오로-N-(2-히드록시-2-메틸 프로폭시)-벤즈아미드,3,4,5-트리플루오로-N-(2-히드록시-2-메틸-프로폭시)-2-(4-요오도-2-메틸 페닐아미노)-벤즈아미드,5-브로모-3,4-디플루오로-N-(2-히드록시-2-메틸-프로폭시)-2-(4-요오도-2-메틸-페닐아미노)-벤즈아미드,5-브로모-2-(2-클로로-4-요오도-페닐아미노)-3,4-디플루오로-N-(2-히드록시-2-메틸-프로폭시)-벤즈아미드,3,4-디플루오로-N-(2-히드록시-2-메틸-프로폭시)-2-(4-요오도-2-메틸 페닐아미노)-벤즈아미드,5-클로로-2-(2-클로로-4-요오도-페닐아미노)-3,4-디플루오로-N-(2-히드록시-2-메틸-프로폭시)-벤즈아미드,5-클로로-3,4-디플루오로-N-(2-히드록시-2-메틸-프로폭시)-2-(4-요오도-2-메틸-페닐아미노)-벤즈아미드,3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(2-히드록시-2-메틸 프로폭시)-벤즈아미드,5-브로모-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(2-히드록시-2 메틸-프로폭시)-벤즈아미드,5-클로로-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(2-히드록시-2 메틸-프로폭시)-벤즈아미드,5-클로로-2-(2,4-디플루오로-페닐아미노)-3,4-디플루오로-N-(2-히드록시-2 메틸-프로폭시)-벤즈아미드,2-(2,4-디플루오로-페닐아미노)-3,4-디플루오로-N-(2-히드록시-2-메틸-프로폭시)-벤즈아미드,2-(4-브로모-2-플루오로-페닐아미노)-3,4-디플루오로-N-(2-히드록시-2-메틸- 프로폭시)-벤즈아미드,2-(2-클로로-4-요오도-페닐아미노)-3,4-디플루오로-N-(2-히드록시-3-페녹시- 프로폭시)-벤즈아미드,2-(2-클로로-4-요오도-페닐아미노)-3,4,5-트리플루오로-N-(2-히드록시-3-페녹시-프로폭시)-벤즈아미드,3,4,5-트리플루오로-N-(2-히드록시-3-페녹시-프로폭시)-2-(4-요오도-2-메틸 페닐아미노)-벤즈아미드,5-브로모-2-(2-클로로-4-요오도-페닐아미노)-3,4-디플루오로-N-(2-히드록시-3-페녹시-프로폭시)-벤즈아미드,5-브로모-3,4-디플루오로-N-(2-히드록시-3-페녹시-프로폭시)-2-(4-요오도-2 메틸-페닐아미노)-벤즈아미드,3,4-디플루오로-N-(2-히드록시-3-페녹시-프로폭시)-2-(4-요오도-2-메틸 페닐아미노)-벤즈아미드,5-클로로-2-(2-클로로-4-요오도-페닐아미노)-3,4-디플루오로-N-(2-히드록시-3-페녹시-프로폭시)-벤즈아미드,5-클로로-3,4-디플루오로-N-(2-히드록시-3-페녹시-프로폭시)-2-(4-요오도-2 메틸-페닐아미노)-벤즈아미드,3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(2-히드록시-3-페녹시 프로폭시)-벤즈아미드,5-클로로-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(2-히드록시-3-페녹시-프로폭시)-벤즈아미드,4,5-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(2-히드록시-3-페녹시 프로폭시)-벤즈아미드,5-클로로-2-(2,4-디플루오로-페닐아미노)-3,4-디플루오로-N-(2-히드록시-3 페녹시-프로폭시)-벤즈아미드,2-(2,4-디플루오로-페닐아미노)-3,4-디플루오로-N-(2-히드록시-3-페녹시-프로폭시)-벤즈아미드,2-(4-클로로-2-플루오로-페닐아미노)-3,4-디플루오로-N-(2-히드록시-3-페녹시-프로폭시)-벤즈아미드,3,4-디플루오로-N-(3-히드록시-2,2-디메틸-프로폭시)-2-(4-요오도-2-메틸 페닐아미노)-벤즈아미드,2-(2-클로로-4-요오도-페닐아미노)-3,4,5-트리플루오로-N-(3-히드록시-2,2 디메틸-프로폭시)-벤즈아미드,3,4,5-트리플루오로-N-(3-히드록시-2,2-디메틸-프로폭시)-2-(4-요오도-2-메틸 페닐아미노)-벤즈아미드,5-클로로-2-(2-클로로-4-요오도-페닐아미노)-3,4-디플루오로-N-(3-히드록시-2,2-디메틸-프로폭시)-벤즈아미드,5-클로로-3,4-디플루오로-N-(3-히드록시-2,2-디메틸-프로폭시)-2-(4-요오도-2-메틸-페닐아미노)-벤즈아미드,3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(3-히드록시-2,2-디메틸-프로폭시)-벤즈아미드,5-클로로-2-(2,4-디플루오로-페닐아미노)-3,4-디플루오로-N-(3-히드록시-2,2 디메틸-프로폭시)-벤즈아미드,3,4-디플루오로-2-(4-요오도-2-메틸-페닐아미노)-N-[2-(2-메톡시 에톡시)-에톡시]-벤즈아미드,3,4,5-트리플루오로-2-(4-요오도-2-메틸-페닐아미노)-N-[2-(2-메톡시 에톡시)-에톡시]-벤즈아미드,5-브로모-3,4-디플루오로-2-(4-요오도-2-메틸-페닐아미노)-N-[2-(2-메톡시-에톡시)-에톡시]-벤즈아미드,2-(2-클로로-4-요오도-페닐아미노)-3,4-디플루오로-N-[2-(2-메톡시-에톡시) 에톡시]-벤즈아미드,2-(2-클로로-4-요오도-페닐아미노)-3,4,5-트리플루오로-N-[2-(2-메톡시 에톡시)-에톡시]-벤즈아미드,5-브로모-2-(2-클로로-4-요오도-페닐아미노)-3,4-디플루오로-N-[2-(2-메톡시-에톡시)-에톡시]-벤즈아미드,3,4,5-트리플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(3,3,3-트리플루오로-2-히드록시-프로폭시)-벤즈아미드,5-클로로-2-(2,4-디플루오로-페닐아미노)-3,4-디플루오로-N-(3,3,3-트리플루오로-2-히드록시-프로폭시)-벤즈아미드,2-(2,4-디플루오로-페닐아미노)-3,4-디플루오로-N-(3,3,3-트리플루오로-2-히드록시 프로폭시)-벤즈아미드,2-(4-클로로-2-플루오로-페닐아미노)-3,4-디플루오로-N-(3,3,3-트리플루오로-2-히드록시-프로폭시)-벤즈아미드,5-클로로-2-(2,4-디플루오로-페닐아미노)-3,4-디플루오로-N-(2-히드록시메틸-시클로프로필메톡시)-벤즈아미드,2-(2,4-디플루오로-페닐아미노)-3,4-디플루오로-N-(2-히드록시메틸 시클로프로필메톡시)-벤즈아미드,2-(4-클로로-2-플루오로-페닐아미노)-3,4-디플루오로-N-(2-히드록시메틸 시클로프로필메톡시)-벤즈아미드,4,5-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(2-히드록시메틸 시클로프로필메톡시)-벤즈아미드,3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(1-히드록시메틸 시클로프로필메톡시)-벤즈아미드,3,4,5-트리플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(1-히드록시메틸 시클로프로필메톡시)-벤즈아미드,5-브로모-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(1-히드록시메틸-시클로프로필메톡시)-벤즈아미드,4,5-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)-N-(1-히드록시메틸 시클로프로필메톡시)-벤즈아미드,2-(2,4-디플루오로-페닐아미노)-3,4-디플루오로-N-(l-히드록시메틸 시클로프로필메톡시)-벤즈아미드,2-(4-브로모-2-플루오로-페닐아미노)-3,4-디플루오로-N-(1-히드록시메틸 시클로프로필메톡시)-벤즈아미드,2-(4-클로로-2-플루오로-페닐아미노)-3,4-디플루오로-N-(1-히드록시메틸-시클로프로필메톡시)-벤즈아미드,5-클로로-2-(2,4-디플루오로-페닐아미노)-3,4-디플루오로-N-(l-히드록시메틸-시클로프로필메톡시)-벤즈아미드,2-(2,4-디플루오로-페닐아미노)-3,4-디플루오로-N-(2-히드록시-3-메톡시-프로폭시)-벤즈아미드,5-클로로-2-(2,4-디플루오로-페닐아미노)-3,4-디플루오로-N-(2-히드록시-3 메톡시-프로폭시)-벤즈아미드,2-(4-브로모-2-플루오로-페닐아미노)-3,4-디플루오로-N-(2-히드록시-3-메톡시-프로폭시)-벤즈아미드, 및2-(4-클로로-2-플루오로-페닐아미노)-3,4-디플루오로-N-(2-히드록시-3-메톡시-프로폭시)-벤즈아미드로 구성된 군으로부터 선택된 화합물.
- N-[(R)-2,3-디히드록시-프로폭시]-3,4-디플루오로-2-(2-플루오로-4-요오도-페닐아미노)벤즈아미드인 화합물.
- 제29항에 있어서, R1은 수소이고, R5은 불소인 화합물.
- 제29항의 화합물 및 약학적으로 허용가능한 담체를 포함하는,발작, 패혈성 쇼크(septic shock), 심부전, 골관절염(osteoarthritis), 류마티스성 관절염(rheumatoid arthritis), 장기 이식 거부 반응(organ transplant rejection), 종양, 암, 재협착(restenosis), 건선(psoriasis), 죽상경화증(atherosclerosis), 이종 이식 거부 증상, 낭성 섬유증(cystic fibrosis), 당뇨병의 합병증, 간종대(hepatomegaly), 심비대(cardiomegaly), 천식, 알츠하이머병, 만성 또는 신경병증성 통증, 또는 바이러스성 감염을 치료하기 위한 약학 조성물.
- 제79항의 화합물 및 약학적으로 허용가능한 담체를 포함하는,발작, 패혈성 쇼크(septic shock), 심부전, 골관절염(osteoarthritis), 류마티스성 관절염(rheumatoid arthritis), 장기 이식 거부 반응(organ transplant rejection), 종양, 암, 재협착(restenosis), 건선(psoriasis), 죽상경화증(atherosclerosis), 이종 이식 거부 증상, 낭성 섬유증(cystic fibrosis), 당뇨병의 합병증, 간종대(hepatomegaly), 심비대(cardiomegaly), 천식, 알츠하이머병, 만성 또는 신경병증성 통증, 또는 바이러스성 감염을 치료하기 위한 약학 조성물.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21937200P | 2000-07-19 | 2000-07-19 | |
US60/219,372 | 2000-07-19 | ||
PCT/US2001/022331 WO2002006213A2 (en) | 2000-07-19 | 2001-07-12 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20030059077A KR20030059077A (ko) | 2003-07-07 |
KR100773621B1 true KR100773621B1 (ko) | 2007-11-05 |
Family
ID=22819013
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020037000810A KR100773621B1 (ko) | 2000-07-19 | 2001-07-12 | 4-요오도 페닐아미노 벤즈히드록삼산의 산소화 에스테르 |
Country Status (43)
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010068738A1 (en) | 2008-12-10 | 2010-06-17 | Dana-Farber Cancer Institute, Inc. | Mek mutations conferring resistance to mek inhibitors |
WO2011106298A1 (en) | 2010-02-25 | 2011-09-01 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
WO2013169858A1 (en) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
Families Citing this family (213)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
YU2503A (sh) * | 2000-07-19 | 2006-05-25 | Warner-Lambert Company | Oksigenovani estri 4-jodo fenilamino benzhidroksamskih kiselina |
IL149462A0 (en) | 2001-05-09 | 2002-11-10 | Warner Lambert Co | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
AU2002310441A1 (en) * | 2001-06-14 | 2003-01-02 | The Regents Of The University Of California | A novel signaling pathway for the production of inflammatory pain and neuropathy |
JP2005515253A (ja) | 2002-01-23 | 2005-05-26 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | N−(4−置換フェニル)−アントラニル酸ヒドロキサメートエステル |
DOP2003000556A (es) | 2002-01-23 | 2003-10-31 | Warner Lambert Co | Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico. |
CN101486682B (zh) * | 2002-03-13 | 2013-08-14 | 阵列生物制药公司 | 作为mek抑制剂的n3烷基化苯并咪唑衍生物 |
US7235537B2 (en) * | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
JP2005526820A (ja) * | 2002-04-09 | 2005-09-08 | ノバルティス アクチエンゲゼルシャフト | 慢性痛の処置のためのmmp7モジュレーターを含む組成物 |
CA2506085A1 (en) * | 2002-11-15 | 2004-06-03 | Ronald Lynn Merriman | Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer |
US7378233B2 (en) | 2003-04-12 | 2008-05-27 | The Johns Hopkins University | BRAF mutation T1796A in thyroid cancers |
US7538120B2 (en) | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
EP1674452A4 (en) * | 2003-09-19 | 2007-10-10 | Chugai Pharmaceutical Co Ltd | NOVEL 4-PHENYLAMINO-BENZALDOXIME DERIVATIVE AND ITS USE AS MEK INHIBITOR |
KR101013932B1 (ko) * | 2003-10-21 | 2011-02-14 | 워너-램버트 캄파니 엘엘씨 | N-[(r)-2,3-디히드록시-프로폭시]-3,4-디플루오로-2-(2-플루오로-4-요오도페닐아미노)-벤자미드 다형체 형태 |
SI1682138T1 (sl) | 2003-11-19 | 2011-04-29 | Array Biopharma Inc | HETEROCIKLIÄŚNI INHIBITORJI MEK-a |
US7732616B2 (en) * | 2003-11-19 | 2010-06-08 | Array Biopharma Inc. | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof |
US7517994B2 (en) * | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
NZ547327A (en) | 2003-11-21 | 2009-08-28 | Array Biopharma Inc | AKT protein kinase inhibitors |
UA89035C2 (ru) * | 2003-12-03 | 2009-12-25 | Лео Фарма А/С | Эфиры гидроксамовых кислот и их фармацевтическое применение |
US20050171182A1 (en) * | 2003-12-11 | 2005-08-04 | Roger Briesewitz | Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases |
CA2561516A1 (en) * | 2004-03-30 | 2005-10-13 | Pfizer Products Inc. | Combinations of signal transduction inhibitors |
US7378423B2 (en) | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
MXPA06014478A (es) | 2004-06-11 | 2007-03-21 | Japan Tobacco Inc | Derivados de 5-amino-2, 4, 7-trioxo-3, 4, 7, 8-tetrahidro -2h-pirido[2, 3-d]pirimidina y compuestos relacionados para el tratamiento del cancer. |
TWI361066B (en) | 2004-07-26 | 2012-04-01 | Chugai Pharmaceutical Co Ltd | 5-substituted-2-phenylamino benzamides as mek inhibitors |
CN101076335A (zh) * | 2004-08-18 | 2007-11-21 | 默克公司 | 有丝分裂驱动蛋白抑制剂 |
EP1802579B1 (en) | 2004-10-20 | 2013-11-20 | Merck Serono SA | Derivatives of 3-arylaminopyridine |
WO2006061712A2 (en) * | 2004-12-10 | 2006-06-15 | Pfizer Inc. | Use of mek inhibitors in treating abnormal cell growth |
US8299076B2 (en) | 2005-05-18 | 2012-10-30 | Array Biopharma Inc. | Crystalline forms of 2-(2-flouro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide |
WO2006134469A1 (en) * | 2005-06-14 | 2006-12-21 | Warner-Lambert Company Llc | Methods of preparing mek inhibitor |
US8101799B2 (en) | 2005-07-21 | 2012-01-24 | Ardea Biosciences | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
ATE504565T1 (de) * | 2005-10-07 | 2011-04-15 | Exelixis Inc | Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen |
WO2007042885A2 (en) * | 2005-10-07 | 2007-04-19 | Pfizer Products Inc. | Therapeutic combination comprising methotrexate and a specified inhibitor of mek1 and mek2 |
EP1790342A1 (de) | 2005-11-11 | 2007-05-30 | Zentaris GmbH | Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege |
WO2007054556A1 (de) | 2005-11-11 | 2007-05-18 | Æterna Zentaris Gmbh | Neue pyridopyrazine und deren verwendung als modulatoren von kinasen |
US8217042B2 (en) | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
GB0601962D0 (en) | 2006-01-31 | 2006-03-15 | Ucb Sa | Therapeutic agents |
US8063050B2 (en) | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
WO2008006032A1 (en) | 2006-07-06 | 2008-01-10 | Array Biopharma Inc. | Cyclopenta [d] pyrimidines as akt protein kinase inhibitors |
US8329701B2 (en) | 2006-07-06 | 2012-12-11 | Array Biopharma Inc. | Dihydrofuro pyrimidines as AKT protein kinase inhibitors |
ATE532789T1 (de) | 2006-07-06 | 2011-11-15 | Array Biopharma Inc | Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren |
MX2009001878A (es) * | 2006-08-21 | 2009-03-03 | Genentech Inc | Compuestos de aza-benzofuranilo y metodos de uso. |
US7893085B2 (en) * | 2006-08-21 | 2011-02-22 | Genentech, Inc | Aza-benzothiophenyl compounds and methods of use |
RU2444524C2 (ru) * | 2006-08-21 | 2012-03-10 | Дженентек, Инк. | Азабензотиофенильные соединения и способы применения |
CN101583616B (zh) * | 2006-08-21 | 2012-05-30 | 健泰科生物技术公司 | 氮杂苯并噻吩基化合物及使用方法 |
KR20090071666A (ko) | 2006-10-23 | 2009-07-01 | 다케다 야쿠힌 고교 가부시키가이샤 | Mapk/erk 키나아제 억제제 |
PL2101759T3 (pl) * | 2006-12-14 | 2019-05-31 | Exelixis Inc | Sposoby stosowania inhibitorów MEK |
JO2985B1 (ar) | 2006-12-20 | 2016-09-05 | Takeda Pharmaceuticals Co | مثبطات كينازmapk/erk |
JP5580735B2 (ja) | 2007-06-12 | 2014-08-27 | ジェネンテック, インコーポレイテッド | N−置換アザインドール類及び使用方法 |
US9409886B2 (en) | 2007-07-05 | 2016-08-09 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
US8846683B2 (en) | 2007-07-05 | 2014-09-30 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors |
EP2173723B3 (en) | 2007-07-05 | 2014-11-19 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
RU2486181C2 (ru) | 2007-07-05 | 2013-06-27 | Эррэй Биофарма Инк. | Пиримидилциклопентаны как ингибиторы акт-протеинкиназ |
GB0714384D0 (en) | 2007-07-23 | 2007-09-05 | Ucb Pharma Sa | theraputic agents |
PE20091158A1 (es) | 2007-12-19 | 2009-08-28 | Genentech Inc | 5-anilinoimidazopiridinas y metodos de uso |
KR20100101666A (ko) | 2007-12-19 | 2010-09-17 | 제넨테크, 인크. | 8-아닐리노이미다조피리딘 및 항암제 및/또는 소염제로서의 이들의 용도 |
AU2008341680A1 (en) | 2007-12-20 | 2009-07-02 | F. Hoffmann-La Roche Ag | Substituted hydantoins as MEK kinase inhibitors |
KR20100099185A (ko) * | 2007-12-21 | 2010-09-10 | 제넨테크, 인크. | 아자인돌리진 및 이용 방법 |
AU2009204019B2 (en) | 2008-01-09 | 2014-02-20 | Array Biopharma Inc. | Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor |
ES2422733T3 (es) | 2008-01-09 | 2013-09-13 | Array Biopharma Inc | Pirimidilciclopentanos hidroxilados como inhibidores de proteínas cinasas AKT |
WO2009093008A1 (en) | 2008-01-21 | 2009-07-30 | Ucb Pharma S.A. | Thieno-pyridine derivatives as mek inhibitors |
GB0811304D0 (en) | 2008-06-19 | 2008-07-30 | Ucb Pharma Sa | Therapeutic agents |
MX2010014559A (es) | 2008-07-01 | 2011-03-04 | Genentech Inc | Heterociclos bicíclicos sustituidos y metodos de uso. |
MX2010014565A (es) | 2008-07-01 | 2011-03-04 | Genentech Inc | Isoindolona y metodos de uso. |
PT2307376E (pt) | 2008-08-04 | 2016-02-26 | Merck Patent Gmbh | Novos compostos de fenilamino-isonicotinamida |
KR20110045095A (ko) | 2008-08-27 | 2011-05-03 | 레오 파마 에이/에스 | Vegfr-2 수용체 및 단백질 티로신 키나아제 억제제인 피리딘 유도체 |
US8278105B2 (en) * | 2008-09-09 | 2012-10-02 | University Of Southern California | Induction, propagation and isolation of liver progenitor cells |
ES2399384T3 (es) | 2008-11-10 | 2013-04-01 | Bayer Schering Pharma Ag | Sulfonamido fenoxibenzamidas sustituidas |
CN102625807B (zh) | 2009-09-08 | 2016-03-09 | 霍夫曼-拉罗奇有限公司 | 4-取代的吡啶-3-基-甲酰胺化合物和使用方法 |
MX2012003546A (es) * | 2009-09-23 | 2012-09-07 | Glaxosmithkline Llc | Combinacion. |
CA2776944A1 (en) * | 2009-10-12 | 2011-05-12 | F. Hoffmann-La Roche Ag | Combinations of a pi3k inhibitor and a mek inhibitor |
EP2491014A1 (en) | 2009-10-21 | 2012-08-29 | Bayer Pharma Aktiengesellschaft | Substituted halophenoxybenzamide derivatives |
WO2011047788A1 (en) | 2009-10-21 | 2011-04-28 | Bayer Schering Pharma Aktiengesellschaft | Substituted benzosulphonamides |
EP2491016A1 (en) | 2009-10-21 | 2012-08-29 | Bayer Pharma Aktiengesellschaft | Substituted benzosulphonamides |
EP2519526B1 (en) | 2009-12-31 | 2014-03-26 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Tricyclic compounds for use as kinase inhibitors |
CA2787714C (en) | 2010-01-22 | 2019-04-09 | Joaquin Pastor Fernandez | Inhibitors of pi3 kinase |
JP2013519719A (ja) | 2010-02-18 | 2013-05-30 | セントロ ナシオナル デ インベスティガシオネス オンコロヒカス(セエネイオ) | トリアゾロ[4,5−b]ピリジン誘導体 |
JP5985401B2 (ja) | 2010-03-09 | 2016-09-06 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | 第一の癌療法に対する耐性を現に有するか、または、そのような耐性を生じる患者において癌を診断および治療する方法 |
WO2011121317A1 (en) | 2010-04-01 | 2011-10-06 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors |
EP2560640A1 (en) | 2010-04-19 | 2013-02-27 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor |
WO2012052745A1 (en) | 2010-10-21 | 2012-04-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Combinations of pi3k inhibitors with a second anti -tumor agent |
JP2013542214A (ja) | 2010-10-29 | 2013-11-21 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 置換フェノキシピリジン類 |
CN102020651B (zh) | 2010-11-02 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 6-芳基氨基吡啶酮甲酰胺mek抑制剂 |
US9732319B2 (en) | 2010-12-22 | 2017-08-15 | Fate Therapeutics, Inc. | Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs |
WO2012098387A1 (en) | 2011-01-18 | 2012-07-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors |
CN102649773A (zh) * | 2011-02-23 | 2012-08-29 | 苏州波锐生物医药科技有限公司 | 氨基芳香烃类化合物及其在制备抗恶性肿瘤药物中的用途 |
CN103857395A (zh) | 2011-04-01 | 2014-06-11 | 基因泰克公司 | Akt抑制剂化合物和阿比特龙的组合及使用方法 |
JP6147246B2 (ja) | 2011-04-01 | 2017-06-14 | ジェネンテック, インコーポレイテッド | Akt及びmek阻害剤化合物の組み合わせ、及び使用方法 |
ES2907071T3 (es) | 2011-05-19 | 2022-04-21 | Fundacion Del Sector Publico Estatal Centro Nac De Investigaciones Oncologicas Carlos Iii F S P Cnio | Compuestos macrocíclicos como inhibidores de proteína quinasas |
EP2524918A1 (en) | 2011-05-19 | 2012-11-21 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyrazines derivates as kinase inhibitors |
WO2012162293A1 (en) * | 2011-05-23 | 2012-11-29 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with mek inhibitors |
WO2012160130A1 (en) | 2011-05-25 | 2012-11-29 | Universite Paris Descartes | Erk inhibitors for use in treating spinal muscular atrophy |
WO2013004984A1 (en) | 2011-07-07 | 2013-01-10 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Tricyclic compounds for use as kinase inhibitors |
WO2013005041A1 (en) | 2011-07-07 | 2013-01-10 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Tricyclic heterocyclic compounds as kinase inhibitors |
WO2013005057A1 (en) | 2011-07-07 | 2013-01-10 | Centro Nacional De Investigaciones Oncológicas (Cnio) | New compounds |
US9416132B2 (en) | 2011-07-21 | 2016-08-16 | Tolero Pharmaceuticals, Inc. | Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors |
WO2013066483A1 (en) | 2011-08-31 | 2013-05-10 | Novartis Ag | Synergistic combinations of pi3k- and mek-inhibitors |
WO2013067165A1 (en) | 2011-11-02 | 2013-05-10 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with platinum-containing agents |
JP2014532712A (ja) | 2011-11-02 | 2014-12-08 | シンタ ファーマシューティカルズ コーポレーション | トポイソメラーゼi阻害剤とhsp90阻害剤の組合せを使用する癌療法 |
CA2854188A1 (en) | 2011-11-14 | 2013-05-23 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with braf inhibitors |
WO2013082511A1 (en) | 2011-12-02 | 2013-06-06 | Genentech, Inc. | Methods for overcoming tumor resistance to vegf antagonists |
CN102532089B (zh) * | 2011-12-22 | 2014-05-14 | 凯莱英医药集团(天津)股份有限公司 | 一种制备手性甘油醇缩丙酮的方法 |
WO2013105022A2 (en) | 2012-01-09 | 2013-07-18 | Novartis Ag | Organic compositions to treat beta-catenin-related diseases |
CN103204822B (zh) | 2012-01-17 | 2014-12-03 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的苯并噁唑化合物及其制备方法和用途 |
BR112014029338A2 (pt) | 2012-05-31 | 2017-06-27 | Bayer Pharma AG | biomarcadores para determinação da resposta eficaz dos tratamentos de pacientes com carcinoma hepatocelular (hcc) |
BR112015008113B1 (pt) | 2012-10-12 | 2022-05-24 | Exelixis, Inc. | Novo processo para preparar compostos para uso no tratamento de câncer |
DK2909181T3 (da) | 2012-10-16 | 2017-11-20 | Tolero Pharmaceuticals Inc | PKM2-modulatorer og fremgangsmåder til anvendelse deraf |
WO2014078669A1 (en) * | 2012-11-15 | 2014-05-22 | Duquesne University Of The Holy Ghost | Carboxylic acid ester prodrug inhibitors of mek |
EP2925366B1 (en) | 2012-11-29 | 2018-02-21 | Novartis AG | Pharmaceutical combinations |
EP2752191A1 (en) | 2013-01-07 | 2014-07-09 | Sanofi | Compositions and methods using hdm2 antagonist and mek inhibitor |
US10139415B2 (en) | 2013-02-27 | 2018-11-27 | Daiichi Sankyo Company, Limited | Method for predicting responsiveness to compound inhibiting MAPK signal transduction pathway |
JP6315848B2 (ja) | 2013-03-13 | 2018-04-25 | ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン | Mek/pi3k二重阻害剤および該阻害剤を使用する治療方法 |
US9498532B2 (en) | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
BR112015022993B1 (pt) | 2013-03-14 | 2021-12-14 | Sumitomo Dainippon Pharma Oncology, Inc. | Inibidores de jak2 e alk2, composição farmacêutica compreendendo os referidos inibidores e uso destes |
EP2968375B1 (en) | 2013-03-14 | 2019-06-12 | MSD International GmbH | Methods for preparing sglt2 inhibitors |
ES2701051T3 (es) | 2013-03-15 | 2019-02-20 | Novartis Ag | Conjugados de anticuerpo-fármaco |
CA2923835C (en) * | 2013-09-11 | 2022-11-29 | The Administrators Of The Tulane Educational Fund | Novel anthranilic amides and the use thereof |
WO2015038704A1 (en) | 2013-09-11 | 2015-03-19 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Compositions for preparing cardiomyocytes |
MX2016006025A (es) | 2013-11-11 | 2016-12-02 | Amgen Inc | Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres. |
CN104788365B (zh) * | 2014-01-16 | 2018-08-10 | 上海艾力斯医药科技有限公司 | 异烟酰胺衍生物、其制备方法及应用 |
EP3805369A1 (en) | 2014-03-04 | 2021-04-14 | Fate Therapeutics, Inc. | Improved reprogramming methods and cell culture platforms |
US10023879B2 (en) | 2014-06-04 | 2018-07-17 | Fate Therapeutics, Inc. | Minimal volume reprogramming of mononuclear cells |
US10786578B2 (en) | 2014-08-05 | 2020-09-29 | Novartis Ag | CKIT antibody drug conjugates |
US9982045B2 (en) | 2014-08-12 | 2018-05-29 | Novartis Ag | Anti-CDH6 antibody drug conjugates |
CN105384754B (zh) * | 2014-09-02 | 2018-04-20 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途 |
CN107206071A (zh) | 2014-09-13 | 2017-09-26 | 诺华股份有限公司 | Alk抑制剂的联合疗法 |
US20170209574A1 (en) | 2014-10-03 | 2017-07-27 | Novartis Ag | Combination therapies |
CA2963091A1 (en) | 2014-10-06 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
WO2016075670A1 (en) | 2014-11-14 | 2016-05-19 | Novartis Ag | Antibody drug conjugates |
WO2016100882A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
LT3237418T (lt) | 2014-12-23 | 2019-05-10 | Novartis Ag | Triazolpirimidino junginiai ir jų panaudojimas |
US10626372B1 (en) | 2015-01-26 | 2020-04-21 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
MX2017012295A (es) | 2015-03-25 | 2018-01-09 | Novartis Ag | Derivados formilados n-heterociclicos como inhibidores de fgfr4. |
MA41866A (fr) | 2015-03-31 | 2018-02-06 | Massachusetts Gen Hospital | Molécules à auto-assemblage pour l'administration ciblée de médicaments |
CN104906081A (zh) * | 2015-05-25 | 2015-09-16 | 上海中医药大学附属曙光医院 | 一种化合物在制备治疗骨关节炎药物中的应用 |
EP3310813A1 (en) | 2015-06-17 | 2018-04-25 | Novartis AG | Antibody drug conjugates |
ES2962460T3 (es) | 2015-08-28 | 2024-03-19 | Novartis Ag | Inhibidores de mdm2 y combinaciones de estos |
AU2016338680B2 (en) | 2015-10-16 | 2022-11-17 | Fate Therapeutics, Inc. | Platform for the induction and maintenance of ground state pluripotency |
MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
CN108368520B (zh) | 2015-11-04 | 2023-01-17 | 菲特治疗公司 | 多能细胞的基因组工程改造 |
US10858628B2 (en) | 2015-11-04 | 2020-12-08 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
CN105646438A (zh) * | 2015-12-22 | 2016-06-08 | 天津大学 | 一种缩酮类糖醇基小分子凝胶因子及其制备方法和应用 |
JP2019502725A (ja) | 2016-01-20 | 2019-01-31 | フェイト セラピューティクス,インコーポレイテッド | 養子免疫療法における免疫細胞調節のための組成物および方法 |
CA3010236A1 (en) | 2016-01-20 | 2017-07-27 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
TWI782906B (zh) | 2016-03-04 | 2022-11-11 | 日商大鵬藥品工業股份有限公司 | 惡性腫瘤治療用製劑及組合物 |
BR112018076443A2 (pt) | 2016-06-20 | 2019-04-09 | Novartis Ag | formas cristalinas de um composto de triazolopirimidina |
EP3472166A1 (en) | 2016-06-20 | 2019-04-24 | Novartis AG | Imidazopyrimidine compounds useful for the treatment of cancer |
JP2019522049A (ja) | 2016-06-20 | 2019-08-08 | ノバルティス アーゲー | トリアゾロピリジン化合物及びその使用 |
JP2019519593A (ja) | 2016-07-06 | 2019-07-11 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガンThe Regents Of The University Of Michigan | MEK/PI3K及びmTOR/MEK/PI3K生物学的経路の多官能性阻害剤、並びに同多官能性阻害剤を用いた治療方法 |
WO2018092064A1 (en) | 2016-11-18 | 2018-05-24 | Novartis Ag | Combinations of mdm2 inhibitors and bcl-xl inhibitors |
WO2018106595A1 (en) | 2016-12-05 | 2018-06-14 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
WO2018146253A1 (en) | 2017-02-10 | 2018-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway |
US11179413B2 (en) | 2017-03-06 | 2021-11-23 | Novartis Ag | Methods of treatment of cancer with reduced UBB expression |
WO2018185618A1 (en) | 2017-04-03 | 2018-10-11 | Novartis Ag | Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment |
AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
CA3057969A1 (en) | 2017-05-02 | 2018-11-08 | Novartis Ag | Combination therapy |
JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
WO2018215938A1 (en) | 2017-05-24 | 2018-11-29 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use |
WO2018215937A1 (en) | 2017-05-24 | 2018-11-29 | Novartis Ag | Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer |
PE20200303A1 (es) | 2017-05-24 | 2020-02-06 | Novartis Ag | Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer |
AR112797A1 (es) | 2017-09-08 | 2019-12-11 | Amgen Inc | Inhibidores de kras g12c y métodos para utilizarlos |
BR112020008888A2 (pt) | 2017-11-16 | 2020-10-20 | Novartis Ag | terapias de combinação |
WO2019181876A1 (ja) | 2018-03-19 | 2019-09-26 | 大鵬薬品工業株式会社 | アルキル硫酸ナトリウムを含む医薬組成物 |
EP3773591A4 (en) | 2018-04-05 | 2021-12-22 | Sumitomo Dainippon Pharma Oncology, Inc. | AXL KINASE INHIBITORS AND THEIR USE |
US11090304B2 (en) | 2018-05-04 | 2021-08-17 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
US11192877B2 (en) | 2018-07-10 | 2021-12-07 | Novartis Ag | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
WO2020021465A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Method of treatment of neuroendocrine tumors |
KR20240033296A (ko) | 2018-07-25 | 2024-03-12 | 어드밴스드 엑셀러레이터 어플리케이션즈 | 안정한 농축 방사성 핵종 복합체 용액 |
EP3826684A4 (en) | 2018-07-26 | 2022-04-06 | Sumitomo Dainippon Pharma Oncology, Inc. | METHODS FOR TREATING DISEASES ASSOCIATED WITH ABNORMAL ACVR1 EXPRESSION AND ACVR1 INHIBITORS FOR USE THEREOF |
EP3837256B1 (en) | 2018-08-17 | 2023-03-08 | Novartis AG | Urea compounds and compositions as smarca2/brm-atpase inhibitors |
US20210346527A1 (en) | 2018-09-25 | 2021-11-11 | Advanced Accelerator Applications (Italy) Srl | Combination Therapy |
WO2020089811A1 (en) | 2018-10-31 | 2020-05-07 | Novartis Ag | Dc-sign antibody drug conjugates |
JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
WO2020128972A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
WO2020167990A1 (en) | 2019-02-12 | 2020-08-20 | Tolero Pharmaceuticals, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
CN113329792A (zh) | 2019-02-15 | 2021-08-31 | 诺华股份有限公司 | 取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
US20220144807A1 (en) | 2019-02-15 | 2022-05-12 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
WO2020198077A1 (en) | 2019-03-22 | 2020-10-01 | Sumitomo Dainippon Pharma Oncology, Inc. | Compositions comprising pkm2 modulators and methods of treatment using the same |
SG11202112855WA (en) | 2019-05-21 | 2021-12-30 | Amgen Inc | Solid state forms |
US11529350B2 (en) | 2019-07-03 | 2022-12-20 | Sumitomo Pharma Oncology, Inc. | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof |
US20220288040A1 (en) | 2019-09-02 | 2022-09-15 | Inserm (Institut National De La Santé Et De La Recherche Médicale)) | Use of pyrvinium for the treatment of a ras pathway mutated acute myeloid leukemia |
CN114746414A (zh) | 2019-09-26 | 2022-07-12 | 诺华公司 | 氮杂-喹啉化合物及其用途 |
US20230056470A1 (en) | 2019-12-20 | 2023-02-23 | Novartis Ag | Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
EP4134081A4 (en) | 2020-04-10 | 2024-05-01 | Taiho Pharmaceutical Co Ltd | CANCER THERAPY USING 3,5-DISUBSTITUTED ALCYNYL BENZENE COMPOUND AND MEK INHIBITOR |
CN116096862A (zh) | 2020-06-11 | 2023-05-09 | 诺华股份有限公司 | Zbtb32抑制剂及其用途 |
WO2021260528A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
EP4188549A1 (en) | 2020-08-03 | 2023-06-07 | Novartis AG | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
AR123185A1 (es) | 2020-08-10 | 2022-11-09 | Novartis Ag | Compuestos y composiciones para inhibir ezh2 |
EP4204020A1 (en) | 2020-08-31 | 2023-07-05 | Advanced Accelerator Applications International S.A. | Method of treating psma-expressing cancers |
EP4204021A1 (en) | 2020-08-31 | 2023-07-05 | Advanced Accelerator Applications International S.A. | Method of treating psma-expressing cancers |
WO2022043556A1 (en) | 2020-08-31 | 2022-03-03 | Novartis Ag | Stable radiopharmaceutical composition |
TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Alk﹘5抑制劑和彼之用途 |
EP4288434A1 (en) | 2021-02-02 | 2023-12-13 | Les Laboratoires Servier | Selective bcl-xl protac compounds and methods of use |
US11066358B1 (en) | 2021-02-17 | 2021-07-20 | Warner-Lambert Company Llc | Compositions of essentially pure form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof |
JP2024507213A (ja) | 2021-02-17 | 2024-02-16 | スプリングワークス、セラピューティクス、インコーポレイテッド | N-((r)-2,3-ジヒドロキシプロポキシ)-3,4-ジフルオロ-2-(2-フルオロ-4-ヨード-フェニルアミノ)-ベンズアミドの分散性製剤及びその使用 |
US11571402B2 (en) | 2021-02-17 | 2023-02-07 | Springworks Therapeutics, Inc. | Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof |
US11084780B1 (en) | 2021-02-17 | 2021-08-10 | Springworks Therapeutics, Inc. | Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof |
CN117500781A (zh) | 2021-02-17 | 2024-02-02 | 沃尼尔·朗伯有限责任公司 | N-((r)-2,3-二羟基丙氧基)-3,4-二氟-2-(2-氟-4-碘-苯氨基)-苯甲酰胺的基本上纯的形式iv的组合物及其用途 |
CN117083264A (zh) | 2021-02-17 | 2023-11-17 | 斯普林渥克斯治疗股份有限公司 | Mek抑制剂n-((r)-2,3-二羟基丙氧基)-3,4-二氟-2-(2-氟-4-碘-苯基氨基)-苯甲酰胺的结晶固体及其用途 |
CN117321418A (zh) | 2021-03-18 | 2023-12-29 | 诺华股份有限公司 | 癌症生物标志物及其使用方法 |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
CN114524753B (zh) * | 2022-02-24 | 2024-03-26 | 安徽大学 | 一种多取代异羟肟酸衍生物的合成方法 |
TW202342018A (zh) | 2022-03-04 | 2023-11-01 | 美商奇奈特生物製藥公司 | Mek激酶抑制劑 |
WO2023178266A2 (en) | 2022-03-17 | 2023-09-21 | SpringWorks Therapeutics Inc. | Fluorinated phenylamino compounds and pharmaceutical compositions |
WO2023209611A1 (en) | 2022-04-26 | 2023-11-02 | Beigene Switzerland Gmbh | Methods of treating cancer with a b-raf inhibitor, in particular lifirafenib |
WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
WO2023223205A1 (en) | 2022-05-17 | 2023-11-23 | Teva Pharmaceuticals International Gmbh | Solid state forms of mirdametinib and process for preparation thereof |
WO2023225320A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
WO2023225336A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
WO2024023666A1 (en) | 2022-07-26 | 2024-02-01 | Novartis Ag | Crystalline forms of an akr1c3 dependent kars inhibitor |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999001426A1 (en) | 1997-07-01 | 1999-01-14 | Warner-Lambert Company | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4368207A (en) * | 1977-05-31 | 1983-01-11 | Block Drug Company Inc. | Higher alcohol toxicants effective against insects |
US5155110A (en) * | 1987-10-27 | 1992-10-13 | Warner-Lambert Company | Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition |
US5783202A (en) * | 1995-03-14 | 1998-07-21 | Soltec Research Pty. Ltd. | Pediculicidal mousse composition for killing head lice |
US6251943B1 (en) * | 1997-02-28 | 2001-06-26 | Warner-Lambert Company | Method of treating or preventing septic shock by administering a MEK inhibitor |
EP0993437B1 (en) | 1997-07-01 | 2006-11-08 | Warner-Lambert Company Llc | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors |
WO2000034228A1 (en) | 1998-12-04 | 2000-06-15 | Neurosearch A/S | Ion channel modulating agents |
KR20010101203A (ko) | 1998-12-15 | 2001-11-14 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | Mek 저해제의 이식 조직 거부를 예방하기 위한 용도 |
JP2002532415A (ja) | 1998-12-16 | 2002-10-02 | ワーナー−ランバート・カンパニー | Mek阻害剤による関節炎の治療 |
YU45401A (sh) * | 1998-12-22 | 2004-07-15 | Warner-Lambert Company | Antikancerogena kombinacija |
US6054493A (en) | 1998-12-30 | 2000-04-25 | The Lubrizol Corporation | Emulsion compositions |
EP1140062B1 (en) | 1999-01-07 | 2005-04-06 | Warner-Lambert Company LLC | Treatment of asthma with mek inhibitors |
WO2000040237A1 (en) * | 1999-01-07 | 2000-07-13 | Warner-Lambert Company | Antiviral method using mek inhibitors |
JP2001055376A (ja) | 1999-01-13 | 2001-02-27 | Warner Lambert Co | ジアリールアミン |
KR20020002370A (ko) * | 1999-01-13 | 2002-01-09 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 벤조헤테로사이클 및 mek 억제제로서의 그의 용도 |
HUP0202623A3 (en) | 1999-07-16 | 2003-03-28 | Warner Lambert Co | Method for treating chronic pain using mek inhibitors |
CA2396693A1 (en) | 1999-12-28 | 2001-07-05 | Stephen T. Wrobleski | Cytokine, especially tnf-alpha, inhibitors |
YU2503A (sh) * | 2000-07-19 | 2006-05-25 | Warner-Lambert Company | Oksigenovani estri 4-jodo fenilamino benzhidroksamskih kiselina |
-
2001
- 2001-07-12 YU YU2503A patent/YU2503A/sh unknown
- 2001-07-12 PL PL365775A patent/PL203387B1/pl unknown
- 2001-07-12 JP JP2002512119A patent/JP3811775B2/ja not_active Expired - Lifetime
- 2001-07-12 KR KR1020037000810A patent/KR100773621B1/ko active IP Right Grant
- 2001-07-12 US US10/333,399 patent/US6960614B2/en not_active Expired - Lifetime
- 2001-07-12 CZ CZ20030069A patent/CZ303815B6/cs not_active IP Right Cessation
- 2001-07-12 PT PT1952778T patent/PT1301472E/pt unknown
- 2001-07-12 EP EP01952778.7A patent/EP1301472B1/en not_active Expired - Lifetime
- 2001-07-12 HU HU0302781A patent/HU230251B1/hu unknown
- 2001-07-12 AP APAP/P/2001/002217A patent/AP2001002217A0/en unknown
- 2001-07-12 NZ NZ524120A patent/NZ524120A/en not_active IP Right Cessation
- 2001-07-12 OA OA1200300002A patent/OA12333A/en unknown
- 2001-07-12 IL IL15381701A patent/IL153817A0/xx unknown
- 2001-07-12 AU AU2001273498A patent/AU2001273498B2/en not_active Expired
- 2001-07-12 EE EEP200300030A patent/EE05450B1/xx unknown
- 2001-07-12 WO PCT/US2001/022331 patent/WO2002006213A2/en active IP Right Grant
- 2001-07-12 SI SI200131033T patent/SI1301472T1/sl unknown
- 2001-07-12 GE GE5067A patent/GEP20053496B/en unknown
- 2001-07-12 CN CNB018140599A patent/CN1219753C/zh not_active Expired - Lifetime
- 2001-07-12 DZ DZ013401A patent/DZ3401A1/fr active
- 2001-07-12 EA EA200300065A patent/EA005818B1/ru not_active IP Right Cessation
- 2001-07-12 DK DK01952778.7T patent/DK1301472T3/da active
- 2001-07-12 SK SK42-2003A patent/SK288317B6/sk not_active IP Right Cessation
- 2001-07-12 CA CA002416685A patent/CA2416685C/en not_active Expired - Lifetime
- 2001-07-12 AP APAP/P/2003/002742A patent/AP2003002742A0/en unknown
- 2001-07-12 BR BR0112584-2 patent/BRPI0112584B8/pt not_active IP Right Cessation
- 2001-07-12 AU AU7349801A patent/AU7349801A/xx active Pending
- 2001-07-12 ES ES01952778.7T patent/ES2461854T3/es not_active Expired - Lifetime
- 2001-07-17 AR ARP010103402A patent/AR033542A1/es active IP Right Grant
- 2001-07-17 TN TNTNSN01108A patent/TNSN01108A1/en unknown
- 2001-07-17 MY MYPI20013387 patent/MY151458A/en unknown
- 2001-07-18 SV SV2001000563A patent/SV2002000563A/es not_active Application Discontinuation
- 2001-07-18 PA PA20018522601A patent/PA8522601A1/es unknown
- 2001-07-18 PE PE2001000725A patent/PE20020664A1/es not_active Application Discontinuation
- 2001-07-18 GT GT200100141A patent/GT200100141A/es unknown
- 2001-07-19 TW TW090117693A patent/TWI311551B/zh not_active IP Right Cessation
- 2001-12-07 UA UA2003021455A patent/UA76425C2/uk unknown
-
2002
- 2002-12-31 IS IS6666A patent/IS6666A/is unknown
-
2003
- 2003-01-14 EC EC2003004430A patent/ECSP034430A/es unknown
- 2003-01-15 MA MA26999A patent/MA26930A1/fr unknown
- 2003-01-17 NO NO20030249A patent/NO328436B1/no not_active IP Right Cessation
- 2003-02-06 HR HR20030083A patent/HRP20030083A2/hr not_active Application Discontinuation
- 2003-02-17 BG BG107564A patent/BG66386B1/bg unknown
- 2003-05-13 ZA ZA200300348A patent/ZA200300348B/en unknown
- 2003-11-13 HK HK03108249A patent/HK1055943A1/xx not_active IP Right Cessation
-
2005
- 2005-04-07 US US11/102,307 patent/US7411001B2/en active Active
-
2014
- 2014-08-25 AR ARP140103181A patent/AR097445A2/es unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999001426A1 (en) | 1997-07-01 | 1999-01-14 | Warner-Lambert Company | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010068738A1 (en) | 2008-12-10 | 2010-06-17 | Dana-Farber Cancer Institute, Inc. | Mek mutations conferring resistance to mek inhibitors |
WO2011106298A1 (en) | 2010-02-25 | 2011-09-01 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
EP3028699A1 (en) | 2010-02-25 | 2016-06-08 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
WO2013169858A1 (en) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100773621B1 (ko) | 4-요오도 페닐아미노 벤즈히드록삼산의 산소화 에스테르 | |
AU2001273498A1 (en) | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | |
US7078438B2 (en) | N-(4 substituted phenyl)-anthranilic acid hydroxamate esters | |
US6770778B2 (en) | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters | |
JP4084189B2 (ja) | 尿素の新誘導体、それらの製造方法、それらの薬剤としての使用、製薬組成物及び新規な用途 | |
FR2490645A1 (fr) | Nouveaux derives phenyliques utiles notamment pour la preparation de medicaments phenylpiperaziniques | |
EP0758330A1 (en) | Biphenylcarboxamides useful as 5-ht1d antagonists | |
MXPA98002097A (en) | Beta3 selecti adrenergic agonists | |
WO2009131171A1 (ja) | 新規5員環化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120927 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20130927 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20140929 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20150930 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20160929 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20170929 Year of fee payment: 11 |